Targeting oestrogen to kill the cancer but not the patient

British Journal of Cancer

Volumn 90, Issue 5, 2004, Pages 944-949

  Lewis, J S ^a   Cheng, D ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Aromatase inhibitor; Estrogen receptor; Raloxifene; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SEX HORMONE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CELL STIMULATION; CELL SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN ACTIVITY; HUMAN; LONG TERM CARE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SHORT SURVEY; TARGET CELL DESTRUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN;

EID: 1942521081     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601627     Document Type: Short Survey

References (28)

1. ATAC Tialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359: 2131-2139
2. Bentrem D, Fox JE, Pearce ST, Liu H, Pappas S, Kupfer D, Zapf JW, Jordan VC (2003) Distinct moleular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res 63: 7490-7496
3. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197
4. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300
5. EBCTCG (1998) Tamoxifen for early breast cancer an overview of the randomised trials. Lancet 351: 1451-1467
6. Emens LA, Davidson NE (2003) Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 9: 486s-489s
7. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
8. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer, updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93: 684-690
9. Goss PE, Ingle JN, Marino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1-10
10. Ingle JN (2002) Estrogen as therapy for breast cancer. Breast Cancer Res 4: 133-136
11. Jensen EV, Jacobson HI (1962) Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18: 387-414
12. Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research. Clin Cancer Res 9: 1980-1989
13. Jiang SY, Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor (see comments). J Natl Cancer Inst 84: 580-591
14. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90: 77-86
15. Jordan VC (2001) Selective estrogen receptor modulation: a personal perspective. Cancer Res 61: 5683-5687
16. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2: 205-213
17. Jordan VC, Osipo C, MacGregor Schafer J, Cheng D, Liu H (2003) Changing role of the oestrogen receptor (ER) in the life and death of breast cancer. The Breast 12: 432-441
18. Lerner LJ, Jordan VC (1990) The development of antiestrogens for the treatment of breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50: 4177-4189
19. Liu H, Lee E-S, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De los Reyes A, Wing L, Jordan VC (2003) Apoptotic action of 17 beta-estradiol in raloxifene resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 1586-1596
20. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116
21. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419-427
22. O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, Jordan VC (2002) Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94: 274-283
23. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark G, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95: 353-361
24. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC (2003) Paradoxical action of fulvestrant on estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1607
25. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ (2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723
26. Wolf DM, Jordan VC (1993) A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 127: 23-33
27. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-333
28. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC (2000) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice (In Process Citation). Clin Cancer Res 6: 2028-2036